Transcatheter Cardiovascular Therapeutics symposium (TCT)
TCT 2013: Higher pacemaker rate marks difference between Medtronic’s, Edwards Lifesciences’ TAVI devices
TCT 2013: Renal denervation does everything
Renal denervation may have lost some of its hype over the course of the last year, but researchers are still findings new ways to utilize the technology to target new diseases.
TCT 2013: Is TAVI cost-effective in operable patients?
TCT 2013: Medtronic unveils full 1-year results from ADVANCE CoreValve trial
TCT 2013: Device makers challenge Big Pharma for stroke prevention in afib patients
TCT 2013: Docs trade barbs over LAA closure
St. Jude Medical slides on negative results from heart implant trial
St. Jude Medical (NYSE:STJ) shares lost 4% today after studies of its Amplatzer heart implant failed to significantly reduce cryptogenic stroke compared with standard treatment with drugs.
Heart valves: Three-year Sapien data buoy Edwards Lifesciences
Edwards Lifesciences’ (NYSE:EW) Sapien transcatheter aortic valve implantation system, the only TAVI device on the U.S. market, demonstrated sustained and increasing survival benefits out to 3 years among inoperable heart failure patients, according to newly unveiled study results.
Selection issues stymie Medtronic’s erectile dysfunction stenting study | MassDevice.com On Call
MASSDEVICE ON CALL — Medical device industry giant Medtronic (NYSE:MDT) is temporarily giving up on its pursuit of erectile dysfunction-treating peripheral stenting, the company told reporters.
Disappointing enrollment experiences led Medtronic to suspend its Impasse trial, an angiography study of pelvic anatomy as associated with erectile dysfunction, which was intended to include 350 patients.